Skip to main content
Evidence-Based Supplement Research
Evidence-Based Supplement Research
Pillser
Search
Sign UpLog In

saccharomyces boulardii

What does the research say about saccharomyces boulardii?

9 health outcomes synthesised

Saccharomyces boulardii is a probiotic yeast studied across 9 health outcomes, primarily for gastrointestinal benefits. The strongest evidence is for reducing diarrhea, with 9 of 9 studies showing beneficial effects at doses ranging from 250 mg/day to 500 mg four times daily, mostly in clinical populations such as patients on antibiotics or undergoing radiotherapy. Other well-researched outcomes include improving Helicobacter pylori eradication rates and reducing related symptoms like abdominal pain and bloating.

Strongest evidence:

  • Reduced Diarrhea (high evidence): 9 of 9 studies found benefit, with moderate effect sizes. Effective doses ranged from 250 mg/day to 500 mg four times daily. Populations included patients with H. pylori infection, pelvic radiotherapy, critical illness, and antibiotic use.
  • Improved H. pylori Eradication Rates (high evidence): 5 of 7 studies showed small but consistent benefits (risk ratios 1.09–1.14). The typical dose was 250 mg twice daily for 14 days.
  • Reduced Diarrhea Rate (moderate evidence): 8 of 10 studies found benefit, primarily in children with acute gastroenteritis or H. pylori infection. Doses of 250–500 mg/day were common.
  • Other moderate-evidence outcomes include increased H. pylori eradication rate (4 of 5 studies), reduced abdominal pain (4 of 5 studies), reduced diarrhea duration (3 of 4 studies), and reduced constipation (3 of 3 studies, large effect sizes).

Mixed or weaker evidence:

  • Reduced Abdominal Distension (low evidence): 3 of 3 studies found benefit, but the evidence base is small and preliminary.
  • Reduced Stool Frequency (low evidence): 3 of 3 studies showed moderate benefit in children, but again based on few studies.
  • Several outcomes have caveats about small sample sizes, inconsistent dosing, and potential publication bias.

Effective dose patterns: The most consistently reported doses across outcomes are 250 mg once or twice daily and 500 mg/day (capsule form). For diarrhea reduction, higher doses up to 500 mg four times daily appeared in some clinical settings. Many studies did not report dose or form, limiting precise recommendations.

Population insights: The majority of evidence comes from clinical populations—patients with H. pylori infection, those on antibiotics or radiotherapy, children with acute gastroenteritis, and critically ill tube-fed patients. Generalizability to healthy individuals is uncertain. Benefits in children were consistent across several outcomes (diarrhea rate, stool frequency, abdominal distension).

Notable caveats:

  • Publication bias is a concern across nearly all outcomes: null results are less likely to be published.
  • Most studies were short-term (median 14 days for several outcomes), with little data on long-term use.
  • Many studies did not specify the form of S. boulardii (capsule, powder, lyophilized) or treatment duration, limiting practical applicability.
  • Effect sizes are often small to moderate, and some meta-analyses show neutral results despite individual positive studies.

Frequently asked

  • What is Saccharomyces boulardii good for according to research?
    Research shows Saccharomyces boulardii is most strongly supported for reducing diarrhea, with 9 of 9 studies reporting benefit. It also appears to improve Helicobacter pylori eradication rates (5 of 7 studies show benefit) and reduce related symptoms like abdominal pain and bloating in clinical populations.
  • What dose of Saccharomyces boulardii is typically used in studies?
    The most common doses are 250 mg once or twice daily, or 500 mg per day in capsule form. For diarrhea reduction, some studies used 250 mg up to 500 mg four times daily. Many studies did not consistently report dosing, so these ranges should be interpreted cautiously.
  • Who benefits most from Saccharomyces boulardii?
    The strongest evidence comes from clinical populations: patients with H. pylori infection (undergoing eradication therapy), children with acute gastroenteritis, hospitalized patients on antibiotics, and patients undergoing pelvic radiotherapy. Benefits in healthy individuals are not well studied.
  • Are there caveats or limitations in the research on Saccharomyces boulardii?
    Yes. Publication bias is a major concern—null results are less likely to be published. Most studies are short-term (often 14 days), and few report long-term outcomes. Many studies do not specify the supplement form or dose, and effect sizes are generally small to moderate. Generalizability beyond specific clinical populations is uncertain.
  • Does Saccharomyces boulardii help with H. pylori eradication?
    Evidence is moderate to high: 5 of 7 studies showed small but statistically significant improvements in eradication rates when added to standard therapy (risk ratios around 1.09–1.14). Two studies found neutral results, and the effect is not large enough to replace standard treatment.
  • Does Saccharomyces boulardii reduce diarrhea in children?
    Yes. For acute gastroenteritis in children, 3 of 4 studies showed reduced diarrhea duration, and 3 of 3 studies found reduced stool frequency with moderate effect sizes. The most common dose was 250 mg twice daily, with benefits typically seen within 3–6 days.
    Back to top